These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 37562081)
1. Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination. Yoo J; Kim Y; Cha YM; Lee J; Jeong YJ; Kim SH; Maragakis LL; Lee S J Infect Public Health; 2023 Oct; 16(10):1537-1543. PubMed ID: 37562081 [TBL] [Abstract][Full Text] [Related]
2. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules. Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050 [TBL] [Abstract][Full Text] [Related]
3. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers. Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR Front Immunol; 2022; 13():968105. PubMed ID: 36211416 [TBL] [Abstract][Full Text] [Related]
7. Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals. Park JS; Jeon J; Um J; Choi YY; Kim MK; Lee KS; Sung HK; Jang HC; Chin B; Kim CK; Oh MD; Lee CS Infect Chemother; 2024 Mar; 56(1):25-36. PubMed ID: 38014726 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A; J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777 [TBL] [Abstract][Full Text] [Related]
9. Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study. Kang JM; Lee J; Huh KH; Joo DJ; Lee JG; Kim HY; Lee M; Jung I; Kim MY; Kim S; Park Y; Kim MS J Clin Virol; 2023 Feb; 159():105374. PubMed ID: 36592547 [TBL] [Abstract][Full Text] [Related]
10. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose. Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064 [TBL] [Abstract][Full Text] [Related]
11. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Poh XY; Tan CW; Lee IR; Chavatte JM; Fong SW; Prince T; Hartley C; Yeoh AYY; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim C; Teo J; Lim DRX; Chia W; Hiscox JA; Ng LFP; Ren EC; Lin RTP; Renia L; Lye DC; Wang LF; Young BE Clin Infect Dis; 2022 Dec; 75(12):2088-2096. PubMed ID: 35543372 [TBL] [Abstract][Full Text] [Related]
12. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents. Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040 [TBL] [Abstract][Full Text] [Related]
14. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial. Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD; J Infect; 2023 Sep; 87(3):230-241. PubMed ID: 37331429 [TBL] [Abstract][Full Text] [Related]
15. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA Front Immunol; 2022; 13():882918. PubMed ID: 35958601 [TBL] [Abstract][Full Text] [Related]
16. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786 [TBL] [Abstract][Full Text] [Related]
17. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990 [TBL] [Abstract][Full Text] [Related]
19. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults. Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]